Listening to Provenge — What a Costly Cancer Treatment Says about Future Medicare Policy

Abstract

Shortly after the FDA approved the costly sipuleucel-T (Provenge) for treating prostate cancer, the Centers for Medicare and Medicaid Services opened a national coverage analysis for the drug, risking duplication of effort and impeded patient access.